BioPharma Resources

Drug Trial Radar · NCT07348692

Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age

A Phase 3, Randomized, Modified Double-blind, Active-controlled, Parallel-group, Lot-to-lot Consistency, 4-arm Study to Investigate the Safety and Immunogenicity of a 4-dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers

Last checked: Nov 19, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 2,195 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

2,195

Planned (sponsor's estimate)

Start

Jan 20, 2026

Primary completion

Jun 7, 2027

Study completion May 29, 2028

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Jan 16, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 42 days, up to 89 days
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a phase 3 randomized, modified double-blind study whose purpose is to measure whether 3 lots of the investigational pneumococcal vaccine PCV21 can help the body to develop germ-fighting agents called "antibodies" (immunogenicity) in a similar way (ie, same immune response) when they are given to infants aged from approximately 2 months (42 to 89 days) and are safe compared to a licensed 20-valent pneumococcal vaccine (20vPCV) (Prevnar 20™). The study duration per participant will be up to approximately 17 months. The study vaccines (either PCV21 or 20vPCV) will be administered at approximately 2, 4, 6 and 12 months of age. Cohort A will include randomization to three PCV21 formulation groups or one 20vPCV comparator group (Group 1-4, approximately 896 total participants), whereas Cohort B will include randomization to three PCV21 formulation groups only (Groups 1-3, approximately 1299 total participants). Routine pediatric vaccines will be given as per local recommendations. There will be 6 study visits: Visit (V)01, V02 separated from V01 by 60 days, V03 separated from V02 by 60 days, V04 separated from V03 by 30 days, V05 at 12 months of age, V06 separated from V05 by 30 days

Conditions

  • Pneumococcal Immunization
  • Healthy Volunteers

Interventions

  • PCV21 vaccineBiological

    Pharmaceutical form: Suspension for injection Route of administration: Intramuscular

  • 20vPCV licensed vaccineBiological

    Pharmaceutical form: Suspension for injection Route of administration: Intramuscular

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. For all participants: Serotype specific Immunoglobulin g (IgG) Geometric Mean Concentration (GMC)Time frame: 30 days after the third dose of PCV21 vaccine

Locations

25 sites in 4 countries. Site status is shown where the registry gives one.

  • Northwest Arkansas Pediatric Clinic- Site Number : 8400039

    Fayetteville, Arkansas · Recruiting

  • Matrix Clinical Research - Huntington Park- Site Number : 8400029

    Huntington Park, California · Recruiting

  • Community Clinical Research- Site Number : 8400030

    Los Angeles, California · Recruiting

  • Matrix Clinical Research - Los Angeles- Site Number : 8400028

    Los Angeles, California · Recruiting

  • PAS Research - Tampa- Site Number : 8400034

    Tampa, Florida · Recruiting

  • Kentucky Pediatric Research- Site Number : 8400036

    Bardstown, Kentucky · Recruiting

  • Michigan Institute of Research- Site Number : 8400004

    Allen Park, Michigan · Recruiting

  • Nappi Wellness Institute\t- Site Number : 8400037

    Syracuse, New York · Recruiting

  • Tribe Clinical Research At Neighbors Pediatrics- Site Number : 8400008

    Charleston, South Carolina · Recruiting

  • Parkside Pediatrics - Simpsonville- Site Number : 8400005

    Simpsonville, South Carolina · Recruiting

  • Tribe Clinical Research - Spartanburg- Site Number : 8400026

    Spartanburg, South Carolina · Recruiting

  • PAS Research - Children's Care Clinic- Site Number : 8400035

    Edinburg, Texas · Recruiting

  • Pediatric Center - Richmond- Site Number : 8400038

    Richmond, Texas · Recruiting

  • Rio Clinical Trials - Canyon View- Site Number : 8400031

    Ogden, Utah · Recruiting

  • Investigational Site Number : 3400001

    San Pedro Sula, Honduras · Recruiting

  • Investigational Site Number : 3400002

    Tegucigalpa, Honduras · Recruiting

  • Investigational Site Number : 3400003

    Tegucigalpa, Honduras · Recruiting

  • Investigational Site Number : 6300005

    Guayama, Puerto Rico · Recruiting

  • Investigational Site Number : 6300006

    San Juan, Puerto Rico · Recruiting

  • Investigational Site Number : 6300007

    Trujillo Alto, Puerto Rico · Recruiting

  • Investigational Site Number : 7640002

    Bangkok, Thailand · Recruiting

  • Investigational Site Number : 7640004

    Chiang Mai, Thailand · Recruiting

  • Investigational Site Number : 7640003

    Hat Yai, Thailand · Recruiting

  • Investigational Site Number : 7640001

    Khon Kaen, Thailand · Recruiting

  • Investigational Site Number : 7640005

    Pathum Wan, Thailand · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.